Hualan Biological Engineering Inc.
002007
Rang in Aktien
#4386
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Aktienkurs
$1.92
Marktkapitalisierung
$3.50B
Veränderung (1 Tag)
-1.39%
Veränderung (1 Jahr)
-19.45%
Land
CN
Handel Hualan Biological Engineering Inc. (002007)
Kategorie
Healthcare
Operative Marge für Hualan Biological Engineering Inc. (002007)
Operative Marge zum October 2026 TTM: 21.31%
Laut den neuesten Finanzberichten und dem Aktienkurs von Hualan Biological Engineering Inc. beträgt die aktuelle operative Marge (TTM) 21.31%. Am Ende des Jahres 2024 lag die operative Marge bei 31.50%.
Historie der operativen Marge von Hualan Biological Engineering Inc. von 2001 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 21.31% | -13.65% |
| 2025 | 24.68% | -21.65% |
| 2024 | 31.50% | -19.81% |
| 2023 | 39.28% | 24.54% |
| 2022 | 31.54% | -17.52% |
| 2021 | 38.24% | -10.68% |
| 2020 | 42.81% | -1.92% |
| 2019 | 43.65% | 0.92% |
| 2018 | 43.25% | 11.81% |
| 2017 | 38.68% | -10.67% |
| 2016 | 43.30% | -4.65% |
| 2015 | 45.41% | -3.26% |
| 2014 | 46.94% | -2.49% |
| 2013 | 48.14% | 55.54% |
| 2012 | 30.95% | -35.41% |
| 2011 | 47.92% | -24.42% |
| 2010 | 63.40% | -2.27% |
| 2009 | 64.87% | 39.09% |
| 2008 | 46.64% | 30.24% |
| 2007 | 35.81% | 33.67% |
| 2006 | 26.79% | 61.78% |
| 2005 | 16.56% | 3.50% |
| 2004 | 16.00% | -4.59% |
| 2003 | 16.77% | -14.87% |
| 2002 | 19.70% | 33.47% |
| 2001 | 14.76% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -98.19% |
US
|
|
| -149.01% | -106.99% |
US
|
|
| 25.57% | -98.80% |
AU
|
|
| 28.81% | -98.65% |
NL
|
|
| 31.23% | -98.53% |
BE
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.